In a first-of-its-kind operation in the United States, a team of doctors at Duke University Hospital helped create a bioengineered blood vessel and transplanted it into the arm of a patient with end-stage kidney disease.
The procedure, the first U.S. clinical trial to test the safety and effectiveness of the bioengineered blood vessel, is a milestone in the field of tissue engineering. The new vein is an off-the-shelf, human cell-based product with no biological properties that would cause organ rejection.
Using technology developed at Duke and at a spin-off company it started called Humacyte, the vein is engineered by cultivating donated human cells on a tubular scaffold to form a vessel. The vessel is then cleansed of the qualities that might trigger an immune response. In pre-clinical tests, the veins have performed better than other synthetic and animal-based implants.
“This is a pioneering event in medicine,” said Jeffrey H. Lawson, M.D., PhD, a vascular surgeon and vascular biologist at Duke Medicine who helped develop the technology and performed the implantation. “It’s exciting to see something you’ve worked on for so long become a reality. We talk about translational technology – developing ideas from the laboratory to clinical practice – and this only happens where there is the multi-disciplinary support and collaboration to cultivate it.”
Clinical trials to test the new veins began in Poland in December with the first human implantations. The U.S. Food and Drug Administration recently approved a phase 1 trial involving 20 kidney dialysis patients in the United States, followed by a safety review. Duke researchers enrolled the first U.S. patient and serve as study leaders.
The initial trial focuses on implanting the vessels in an easily accessible site in the arms of kidney hemodialysis patients. More than 350,000 people in the United States require hemodialysis, which often necessitates a graft to connect an artery to a vein to speed blood flow during treatments. Current options have drawbacks. Synthetic vascular grafts are prone to clotting, leading to frequent hospitalizations, and harvesting veins from the patient’s own body involves a separate procedure, with the risk of infection and other complications.
If the bioengineered veins prove beneficial for hemodialysis patients, the researchers ultimately aim to develop a readily available and durable graft for heart bypass surgeries, which are performed on nearly 400,000 people in the United States a year, and to treat blocked blood vessels in the limbs.
“We hope this sets the groundwork for how these things can be grown, how they can incorporate into the host, and how they can avoid being rejected immunologically,” Lawson said. “A blood vessel is really an organ – it’s complex tissue. We start with this, and one day we may be able to engineer a liver or a kidney or an eye.”
The bioengineered vein is the product of a 15-year collaboration between Lawson and Laura Niklason, M.D., PhD, co-founder of Humacyte and a former faculty member at Duke who is now at Yale. Lawson and Niklason teamed up in the late 1990s after discovering they shared an interest in engineering blood vessels.
Building on work Niklason began as a bioengineering post-doctoral student, the duo worked to perfect the technology in animal models and eventually moved to develop veins for human implantation.
“The bioengineered blood vessel technology is a new paradigm in tissue engineering,” said Niklason, professor and vice chair of anesthesia, professor of biomedical engineering, Yale University, and founder of Humacyte. “This technology is a key step for patients with end-stage renal disease and can potentially avoid surgical interventions and hospitalizations. The fact that these vessels contain no living cells enables simple storage onsite at hospitals, making them the first off-the-shelf engineered grafts that have transitioned into clinical evaluation.”
Overcoming setbacks and frustrations, the researchers notched numerous advancements, starting with the biodegradable mesh as the scaffolding for the veins. The mesh, easily manipulated into any shape, is formed into a blood vessel of varying lengths and widths.
When seeded with smooth muscle cells, the mesh gradually dissolves as the cells grow in a special medium of amino acids, vitamins and other nutrients. One key improvement, which strengthens the bioengineered tissue, is a pulsing force introduced during the growth process, in which the nutrients are pumped through the tube in a heartbeat rhythm to build the physical properties that are similar to native blood vessels.
After a couple of months, a life-like vein results.
The Latest Bing News on:
Bioengineered Vein
- Recognizing and Treating Venous Stasis Ulcerson July 29, 2022 at 5:00 pm
The incidence of VSUs is most prevalent among the elderly population and is also ubiquitous in patients with a medical history of edema in the legs, long-standing varicose veins, or blood clots in ...
- Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery ...on July 25, 2022 at 6:23 pm
Saphenous vein grafts are used in 80-90% of CABG procedures ... biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed ...
- U of M granted $3.7 million for research to reduce surgeries for pediatric heart patientson July 20, 2022 at 9:47 am
The clinical trial would help to improve treatment for children who were born with heart defects because patients often outgrow vessel grafts, the current method, meaning they require a series of ...
- Medical Microinstruments raises $75M for robotic microsurgeryon July 20, 2022 at 7:42 am
Robotic microsurgery company Medical Microinstruments announced today that it raised $75 million in a Series B financing round.
- Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trialon July 19, 2022 at 1:15 pm
Researchers at the University of Minnesota received a $3.7 million grant to prepare for a trial of artificial, bioengineered blood vessels.
- U of M granted $3.7 million for research to reduce surgeries for pediatric heart patientson July 18, 2022 at 3:11 pm
Researchers will test bioengineered blood vessels that grow with the patient, the university says. The trial aims to improve treatment for children who were born with heart defects because ...
- Researchers Work to Grow Capillaries Inside 3D Printed Moldson July 10, 2022 at 5:00 pm
Researchers at Rice University and Baylor College of Medicine have overcome an important challenge to using endothelial cells sourced from induced pluripotent stem cells to generate bioengineered ...
- Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Traumaon July 8, 2022 at 12:59 pm
DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...
- Humacyte Hosting Key Opinion Leader Webinar On Human Acellular Vessels™ In The Treatment Of Vascular Traumaon July 7, 2022 at 5:43 am
About HAV Human Acellular Vessels (HAV) are investigational engineered ... biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ ...
- Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels(TM) in the Treatment of Vascular Traumaon July 7, 2022 at 5:01 am
HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) ...
The Latest Google Headlines on:
Bioengineered Vein
The Latest Bing News on:
Bioengineered blood vessel
- Tissue Engineered Skin Substitute Market is estimated for a robust 9.6% CAGR during 2022 – 2029on July 29, 2022 at 5:45 am
3D bioprinting and biotextile are emerging as popular biofabrication strategies for creating bioengineered skin substitutes ... for complete 3D printing of the living skin along with blood vessels.
- Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery ...on July 25, 2022 at 6:23 pm
DURHAM, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at ...
- A Milestone in 3D-Printed Organson July 25, 2022 at 5:00 pm
The 3D-printed constructs are biocompatible and support new blood vessel growth into the transplanted material ... One approach is fabricating lungs in the lab by combining cells with a bioengineered ...
- Merit Medical launches smallest, shortest configuration of pulmonary balloon dilatoron July 20, 2022 at 9:53 am
Merit Medical Systems (Nasdaq:MMSI) announced today that it launched the smallest and shortest configuration of its Elation portfolio.
- U of M granted $3.7 million for research to reduce surgeries for pediatric heart patientson July 20, 2022 at 9:47 am
The clinical trial would help to improve treatment for children who were born with heart defects because patients often outgrow vessel grafts, the current method, meaning they require a series of ...
- Medical Microinstruments raises $75M for robotic microsurgeryon July 20, 2022 at 7:42 am
Robotic microsurgery company Medical Microinstruments announced today that it raised $75 million in a Series B financing round.
- Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trialon July 19, 2022 at 1:15 pm
Researchers at the University of Minnesota received a $3.7 million grant to prepare for a trial of artificial, bioengineered blood vessels.
- U of M granted $3.7 million for research to reduce surgeries for pediatric heart patientson July 18, 2022 at 3:11 pm
Researchers will test bioengineered blood vessels that grow with the patient, the university says. The trial aims to improve treatment for children who were born with heart defects because ...
- Researchers Can Now Bioengineer Lungs with the Original Blood Vessels Intacton July 15, 2022 at 5:00 pm
Most bioengineered lungs are built using scaffolds constructed from completely decellularized lungs. Unlike those scaffolds, this project keeps the vascular network of the original lung intact ...
- Researchers Work to Grow Capillaries Inside 3D Printed Moldson July 10, 2022 at 5:00 pm
Specifically, the investigators were able to watch and guide the formation of tiny blood vessels within specially built molds that promote cellular ingrowth. This development should help ...